Literature DB >> 31240424

Multiple primary malignancies associated with a germline SMARCB1 pathogenic variant.

Judith A Eelloo1, Miriam J Smith2,3, Naomi L Bowers2, John Ealing2,4, Paul Hulse5, James P Wylie6, Patrick Shenjere7, Noel W Clarke8, Calvin Soh9, Richard W Whitehouse9, Mark Jones10, Christopher Duff11, Anthony Freemont12, D Gareth Evans2,3.   

Abstract

A 51-year old presented with a 6-month history of increasing pelvic/lower back pain with nocturnal waking and episodes of anorexia and vomiting. Examination revealed right torticollis and Horner's syndrome, and a large abdominal mass arising from the pelvis. Magnetic resonance and positron emission tomography imaging revealed (A) a 14 cm heterogeneous enhancing mass, abutting the left kidney with standardised uptake value max = 2.9, (B) a large heterogeneous enhancing pelvic mass (C) mesenteric adenopathy standardised uptake value max = 10.3 and (D) 6 cm right lung apex mass standardised uptake value max = 4.3. Computerised tomography-guided biopsy of lesion A was reported as neurofibroma with occasional atypia, lesion B a benign uterine leiomyoma and lesion C follicular lymphoma world health organisation Grade 2. Although she had been given the diagnosis of Neurofibromatosis Type-1 (NF1) 25-years previously following removal of an intradural extramedullary schwannoma she had no cutaneous stigmata of NF1. Genetic analysis of blood lymphocyte DNA identified a pathogenic variant in SMARCB1 confirming a diagnosis of schwannomatosis. Following 6-months chemotherapy for lymphoma, surgery was performed to remove lesion A. Histology revealed a malignant peripheral nerve sheath tumour with areas of low and high-grade change. An incidental, well-differentiated small bowel neuroendocrine carcinoma was also excised. Close surveillance continues with no recurrence after 6 years. This case study describes a novel finding of three separate synchronous primary malignancies in a patient with schwannomatosis and a proven SMARCB1 pathogenic variant.

Entities:  

Keywords:  Follicular lymphoma; MPNST; Malignancy; Neurofibromatosis type 1; Neurofibromatosis type 2; SMARCB1; Schwannomatosis

Mesh:

Substances:

Year:  2019        PMID: 31240424     DOI: 10.1007/s10689-019-00138-4

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  15 in total

1.  Broadening the spectrum of SMARCB1-associated malignant tumors: a case of uterine leiomyosarcoma in a patient with schwannomatosis.

Authors:  Irene Paganini; Roberta Sestini; Matilde Cacciatore; Gabriele L Capone; Luisa Candita; Concetta Paolello; Marta Sbaraglia; Angelo P Dei Tos; Sabrina Rossi; Laura Papi
Journal:  Hum Pathol       Date:  2015-05-06       Impact factor: 3.466

2.  Hybrid neurofibroma/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients.

Authors:  Anja Harder; Martin Wesemann; Christian Hagel; Jens Schittenhelm; Susan Fischer; Marcos Tatagiba; Christoph Nagel; Astrid Jeibmann; Axel Bohring; Victor-Felix Mautner; Werner Paulus
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

Review 3.  Diagnostic criteria for schwannomatosis.

Authors:  M MacCollin; E A Chiocca; D G Evans; J M Friedman; R Horvitz; D Jaramillo; M Lev; V F Mautner; M Niimura; S R Plotkin; C N Sang; A Stemmer-Rachamimov; E S Roach
Journal:  Neurology       Date:  2005-06-14       Impact factor: 9.910

4.  Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors.

Authors:  Katherine W Eaton; Laura S Tooke; Luanne M Wainwright; Alexander R Judkins; Jaclyn A Biegel
Journal:  Pediatr Blood Cancer       Date:  2011-01       Impact factor: 3.167

5.  SMARCB1 involvement in the development of leiomyoma in a patient with schwannomatosis.

Authors:  Theo J M Hulsebos; Susan Kenter; Ulrike Siebers-Renelt; Volkmar Hans; Pieter Wesseling; Uta Flucke
Journal:  Am J Surg Pathol       Date:  2014-03       Impact factor: 6.394

6.  Schwannomatosis: a genetic and epidemiological study.

Authors:  D Gareth Evans; Naomi L Bowers; Simon Tobi; Claire Hartley; Andrew J Wallace; Andrew T King; Simon K W Lloyd; Scott A Rutherford; Charlotte Hammerbeck-Ward; Omar N Pathmanaban; Simon R Freeman; John Ealing; Mark Kellett; Roger Laitt; Owen Thomas; Dorothy Halliday; Rosalie Ferner; Amy Taylor; Chris Duff; Elaine F Harkness; Miriam J Smith
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-06-16       Impact factor: 10.154

7.  Premature termination of SMARCB1 translation may be followed by reinitiation in schwannomatosis-associated schwannomas, but results in absence of SMARCB1 expression in rhabdoid tumors.

Authors:  Theo J M Hulsebos; Susan Kenter; Wim I M Verhagen; Frank Baas; Uta Flucke; Pieter Wesseling
Journal:  Acta Neuropathol       Date:  2014-04-17       Impact factor: 17.088

8.  Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1.

Authors:  J J Swensen; J Keyser; C M Coffin; J A Biegel; D H Viskochil; M S Williams
Journal:  J Med Genet       Date:  2009-01       Impact factor: 6.318

9.  Nerve sheath tumours with hybrid features of neurofibroma and schwannoma: a conceptual challenge.

Authors:  M B Feany; D C Anthony; C D Fletcher
Journal:  Histopathology       Date:  1998-05       Impact factor: 5.087

10.  Malignant peripheral nerve sheath tumours in inherited disease.

Authors:  D Gareth R Evans; Susan M Huson; Jillian M Birch
Journal:  Clin Sarcoma Res       Date:  2012-10-04
View more
  1 in total

1.  ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis.

Authors:  D Gareth Evans; Stefania Mostaccioli; David Pang; Mary Fadzil O Connor; Melpo Pittara; Nicolas Champollion; Pierre Wolkenstein; Nick Thomas; Rosalie E Ferner; Michel Kalamarides; Matthieu Peyre; Laura Papi; Eric Legius; Juan Luis Becerra; Andrew King; Chris Duff; Stavros Stivaros; Ignacio Blanco
Journal:  Eur J Hum Genet       Date:  2022-04-01       Impact factor: 5.351

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.